Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + PTCy for GVHD Prophylaxis After Reduced Intensity Conditioning Matched Donor HCT
NCT05364762Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Dec 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in graft-versus-host disease (GVHD), sponsored by City of Hope. Started Dec 2022; status: active, not recruiting.
02
Drugs
itacitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05364762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364762.